Can Inflammatory Markers From CSF Be Helpful In Diagnosis Of Multiple Sclerosis? (P4.137)

2014 
OBJECTIVE: We hypothesized the levels of some markers could be changed in MS in comparison with controls. We studied five inflammatory markers (interleukin-6, interleukin-8, interleukin-10, beta-2-microglobulin, orosomucoid). BACKGROUND: MS is an inflammatory-demyelinating disease of the CNS. Especially an autoimmune inflammation participates in the early stages of MS. This stage is followed by the neurodegenerative process. There are more studies dealing with biomarkers in CSF and their role in diagnosis and treatment of MS. METHODS: The study was based on CSF and serum examination in patients with MS and control group (patients with non-inflammatory disease). The lumbar puncture was indicated for diagnostic purposes in patients with suspected MS. None of our patients had been treated by corticosteroids before lumbar puncture. The aim of the study was to assess CSF and serum levels of inflammatory markers and compare these levels between group of MS patients and control group. RESULTS: We investigated group of 66 patients. CSF and serum examination was performed in 38 patients with newly diagnosed MS fulfilling McDonald9s revised diagnostic criteria (25 females,13 males; mean age 35,8 ± 9,1 years) and 28 control group patients (20 females, 8 males; mean age 39,7 ± 13,0 years). No statistical significant differences in demographic data between patients and control group were found. Significantly higher CSF levels of IL-8 (52,8 (41,6-68,3); p<0.001, Mann-Whitney U test) andbeta-2-microglobulin (1,26 (1,03-1,37); p=0.007, Mann-Whitney U test) in MS patients group were found. No differences in others CSF markers and serum levels of all markers between both groups were found. CONCLUSIONS: There are a lot of various studies dealing with inflammatory markers. Some of them confirm our results, others not. The etiology of MS is still unknown. This is the reason to continue in researching of inflammatory and neurodegenerative markers in MS. The knowledge of etiology can bring a new look for the treatment. Disclosure: Dr. Matejcikova has nothing to disclose. Dr. Prikrylova-Vranova has nothing to disclose. Dr. Klosova has nothing to disclose. Dr. Sladkova has nothing to disclose. Dr. Zapletalova has nothing to disclose. Dr. Mares has nothing to disclose. Dr. Kanovsky has nothing to disclose.
    • Correction
    • Source
    • Cite
    • Save
    • Machine Reading By IdeaReader
    0
    References
    0
    Citations
    NaN
    KQI
    []